224 related articles for article (PubMed ID: 33678104)
1. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
[No Abstract] [Full Text] [Related]
2. Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Zhao Q; Guo M; Hostetter TH; Chen H; Lin L; Hai X
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1173-1182. PubMed ID: 34181499
[No Abstract] [Full Text] [Related]
3. Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
Guo S; Wang X; Gao C; Wu Z; Chen H; Lin L; Guo M; Gao Y; Hai X
Toxicol Lett; 2021 Sep; 347():78-85. PubMed ID: 33865921
[TBL] [Abstract][Full Text] [Related]
4. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
[TBL] [Abstract][Full Text] [Related]
5. Speciation analysis of arsenic in urine samples from APL patients treated with single agent As
Guo M; Li J; Fan S; Liu W; Wang B; Gao C; Zhou J; Hai X
J Pharm Biomed Anal; 2019 Jul; 171():212-217. PubMed ID: 31009876
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia.
Gao C; Hu S; Guo M; Hai X; Zhou J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):229-236. PubMed ID: 29845392
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of arsenic species in cerebrospinal fluid (CSF) of acute promyelocytic leukaemia (APL) patients treated with arsenic trioxide plus mannitol.
Guo M; Zhao Q; Fan S; Wu Z; Lin L; Chen H; Gao Y; Hai X
Br J Clin Pharmacol; 2021 Oct; 87(10):4020-4026. PubMed ID: 33638869
[TBL] [Abstract][Full Text] [Related]
8. Arsenic Trioxide Therapy During Pregnancy: ATO and Its Metabolites in Maternal Blood and Amniotic Fluid of Acute Promyelocytic Leukemia Patients.
Guo M; Lv J; Chen X; Wu M; Zhao Q; Hai X
Front Oncol; 2022; 12():887026. PubMed ID: 35646703
[TBL] [Abstract][Full Text] [Related]
9. Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients.
Lv J; Wu M; Pang C; Duan R; Zhang H; Tian S; Yang H; Hai X
Biomed Pharmacother; 2023 Jul; 163():114858. PubMed ID: 37172335
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
11. HPLC-HG-AFS determination of arsenic species in acute promyelocytic leukemia (APL) plasma and blood cells.
Guo M; Wang W; Hai X; Zhou J
J Pharm Biomed Anal; 2017 Oct; 145():356-363. PubMed ID: 28711674
[TBL] [Abstract][Full Text] [Related]
12. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
13. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
[TBL] [Abstract][Full Text] [Related]
15. Effect of continuous venovenous haemodialysis on outcome and pharmacokinetics of arsenic species in a patient with acute promyelocytic leukaemia and acute kidney injury.
Gao C; Fan S; Hostetter TH; Wang W; Li J; Guo M; Zhou J; Hai X
Br J Clin Pharmacol; 2019 Apr; 85(4):849-853. PubMed ID: 30677159
[TBL] [Abstract][Full Text] [Related]
16. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Wang Z; Zhou J; Lu X; Gong Z; Le XC
Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
[TBL] [Abstract][Full Text] [Related]
17. Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide.
Lu J; Yu K; Fan S; Liu W; Dong Z; Li J; Wang X; Hai X; Zhou J
Toxicol Appl Pharmacol; 2019 Sep; 379():114687. PubMed ID: 31330140
[TBL] [Abstract][Full Text] [Related]
18. Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide.
Zhang Z; Chen Y; Meng H; Sui M; Zhou Q; Shi C; Han L; Wang H; Zhou J
Leuk Lymphoma; 2013 Sep; 54(9):2041-6. PubMed ID: 23343178
[TBL] [Abstract][Full Text] [Related]
19. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
Maimaitiyiming Y; Zhu HH; Yang C; Naranmandura H
Drug Metab Rev; 2020 Aug; 52(3):425-437. PubMed ID: 32677488
[TBL] [Abstract][Full Text] [Related]
20. Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.
Iriyama N; Yoshino Y; Yuan B; Horikoshi A; Hirabayashi Y; Hatta Y; Toyoda H; Takeuchi J
J Hematol Oncol; 2012 Jan; 5():1. PubMed ID: 22272800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
